The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Open accessAbstract
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. RESULTS: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vemurafenib, a selective oral inhibitor of the BRAF V600 kinase, achieved an approximately 50% response and improved survival among metastatic melanoma patients with the BRAF V600E mutation [97].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [97]
In the citing paper
“Maturation of survival data also increased the ESMO-MCBS score of vemurafenib in the treatment of metastatic melanoma [116, 117] from ESMO-MCBS 3 based on PFS to 4, based on OS.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Research works printed but not linked: 1
- Kumar R, 2003, Clin Cancer Res, 9, 3362
Cited by
Sorted by citations
Items 501–600 of 1,053
Mann, G. J., Pupo, G. M., Campain, A. E., Carter, C. D., Schramm, S., Pianova, S., Gerega, S. K., Silva, C. D., Lai, K., Wilmott, J. S., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.283 · Cited by 183
Metabolic Plasticity in Chemotherapy Resistance
Desbats, M. A., Giacomini, I., Prayer‐Galetti, T., & Montopoli, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00281 · Cited by 190
“Chapman and co-workers demonstrated that its inhibition with vemurafenib leads to the shift to OxPhos and the switch is useful to treat resistant melanoma cells (331).”
BackgroundWhich drug, and when, for patients with BRAF-mutant melanoma?
Jang, S., & Atkins, M. B. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70539-9 · Cited by 182
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza‐Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Schwaederle, M. C., Parker, B. A., Schwab, R. B., Daniels, G. A., Piccioni, D. E., Kesari, S., Helsten, T. L., Bazhenova, L. A., Romero, J., Fanta, P. T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0795 · Cited by 184
Mittapalli, R. K., Vaidhyanathan, S., Dudek, A. Z., & Elmquist, W. F. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201475 · Cited by 182
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
Chu, E. Y., Wanat, K. A., Miller, C. J., Amaravadi, R. K., Fecher, L. A., Brose, M. S., McGettigan, S., Giles, L. R., Schuchter, L. M., Seykora, J. T., et al. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.04.008 · Cited by 182
Melanoma: What do all the mutations mean?
Davis, E. J., Johnson, D. B., Sosman, J. A., & Chandra, S. (2018) · Cancer · doi:10.1002/cncr.31345 · Cited by 197
Self-citationAscierto, P. A., Dummer, R., Gogas, H. J., Flaherty, K. T., Arance, A. M., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.016 · Cited by 181
Self-citationCorazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet‐Martino, M., Balayssac, S., Rocchi, S., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1420 · Cited by 188
Development of encorafenib for BRAF-mutated advanced melanoma
Koelblinger, P., Olaf, T., & Dummer, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000426 · Cited by 191
Self-citationHoward, J. H., Thompson, J. F., Mozzillo, N., Nieweg, O. E., Hoekstra, H. J., Roses, D. F., Sondak, V. K., Reintgen, D. S., Kashani–Sabet, M., Karakousis, C. P., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2398-z · Cited by 178
Melanoma treatment: from conventional to nanotechnology
Mishra, H., Mishra, P. K., Ekielski, A., Jaggi, M., Iqbal, Z., & Talegaonkar, S. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2726-1 · Cited by 189
FAK in Cancer: From Mechanisms to Therapeutic Strategies
Chuang, H.-H., Zhen, Y., Tsai, Y.-C., Chuang, C., Hsiao, M., Huang, M., & Yang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031726 · Cited by 193
“The Ras–RAF–MEK signaling pathway is often aberrantly upregulated in various cancers, and Ras and RAF are frequently mutated genes, contributing to a worse prognosis [203,204].”
BackgroundBRAF V600E Inhibition in Anaplastic Thyroid Cancer
Rosove, M. H., Peddi, P. F., & Glaspy, J. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215697 · Cited by 178
McArthur, G. A., Puzanov, I. J., Amaravadi, R. K., Ribas, A., Chapman, P. B., Kim, K. B., Sosman, J. A., Lee, R. J., Nolop, K. B., Flaherty, K. T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1938 · Cited by 176
Self-citationTIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., van Rooij, N., Linnemann, C., van Buuren, M. M., Urbanus, J. H. M., et al. (2012) · OncoImmunology · doi:10.4161/onci.18851 · Cited by 178
Self-citationA genetic basis for the variation in the vulnerability of cancer to DNA damage
Yard, B. D., Adams, D., Chie, E. K., Tamayo, P., Battaglia, J., Gopal, P., Rogacki, K. R., Pearson, B. E., Phillips, J. G., Raymond, D. P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11428 · Cited by 188
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Buchbinder, E. L., & Hodi, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80012 · Cited by 181
Biomarker enrichment strategies: matching trial design to biomarker credentials
Freidlin, B., & Korn, E. L. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.218 · Cited by 183
Reinwald, M., Silva, J. T., Mueller, N. J., Fortün, J., Garzoni, C., de Fijter, J. W., Fernández‐Ruiz, M., Grossi, P., & Aguado, J. M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.009 · Cited by 178
Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3937 · Cited by 179
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Anastas, J. N., Kulikauskas, R. M., Tamir, T. Y., Rizos, H., Long, G. V., von Euw, E. M., Yang, P., Chen, H., Haydu, L. E., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 184
Cutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P. M., & Sekulić, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.033 · Cited by 178
Guo, J., Carvajal, R. D., Dummer, R., Hauschild, A., DAUD, A. I., Bastian, B. C., Markovic, S. N., Queirolo, P., Arance, A. M., Berking, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx079 · Cited by 176
Self-citationPhenotypes in acute respiratory distress syndrome: moving towards precision medicine
Sinha, P., & Calfee, C. S. (2018) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000571 · Cited by 182
Targeting ALK in neuroblastoma—preclinical and clinical advancements
Carpenter, E. L., & Mossé, Y. P. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.72 · Cited by 177
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
Gramont, A. D. E., Watson, S., Ellis, L. M., Rodon, J. A., Tabernero, J. M., de Gramont, A., & Hamilton, S. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.202 · Cited by 179
Pencheva, N., Buss, C. G., Posada, J., Merghoub, T., & Tavazoie, S. F. (2014) · Cell · doi:10.1016/j.cell.2014.01.038 · Cited by 175
Emerging strategies for treating metastasis
Esposito, M., Ganesan, S., & Kang, Y. (2021) · Nature Cancer · doi:10.1038/s43018-021-00181-0 · Cited by 175
Aarntzen, E. H. J. G., de Vries, I. J. M., Lesterhuis, W. J., Schuurhuis, D. H., Jacobs, J. F. M., Bol, K. F., Schreibelt, G., Mus, R. D. M., de Wilt, J. H. W., Haanen, J. B. A. G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1127 · Cited by 170
Self-citationLi, Y., Choi, P. S., Casey, S. C., Dill, D. L., & Felsher, D. W. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.014 · Cited by 181
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Shi, H., Hong, A., Kong, X., Koya, R. C., Song, C., Moriceau, G., Hugo, W., Yu, C. C., Ng, C., Chodon, T., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0279 · Cited by 178
Self-citationSurvival of patients with advanced metastatic melanoma: The impact of novel therapies
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P. C., McArthur, G. A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.013 · Cited by 179
Self-citationCurrent Advances in the Treatment of BRAF-Mutant Melanoma
Patel, H. M., Yacoub, N., Mishra, R., White, A., Yuan, L., Alanazi, S., & Garrett, J. T. (2020) · Cancers · doi:10.3390/cancers12020482 · Cited by 184
“The FDA approval was granted based on the Phase 3 trial (BRIM-3) results (NCT01006980) which exhibited improved overall survival and progression-free survival rate in patients with BRAFV600E mutant melanoma [188].”
BackgroundManagement of brain metastases according to molecular subtypes
Soffietti, R., Ahluwalia, M. S., Lin, N., & Rudà, R. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0391-x · Cited by 175
Diagnostic and prognostic biomarkers in melanoma.
Weinstein, D. M., Leininger, J., Hamby, C. V., & Safai, B. (2014) · PubMed Central · Cited by 172
BRAF V600E mutation-specific antibody: A review
Ritterhouse, L. L., & Barletta, J. A. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.010 · Cited by 175
Decker, B. J., Parker, H. G., Dhawan, D., Kwon, E. M., Karlins, E., Davis, B. W., Ramos, J. A., Bonney, P. L., McNiel, E. A., Knapp, D. W., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0689 · Cited by 175
Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth
Dewaele, M., Tabaglio, T., Willekens, K., Bezzi, M., Teo, S. X., Low, D. H. P., Koh, C. M., Rambow, F., Fiers, M. W. E. J., Rogiers, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82534 · Cited by 182
Anforth, R. M., Blumetti, T. C. M. P., Kefford, R. F., Sharma, R., Scolyer, R. A., Kossard, S., Long, G. V., & Fernández‐Peñas, P. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11155.x · Cited by 172
KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
Zebary, A., Jangard, M., Omholt, K., Ragnarsson-Olding, B. K., & Hansson, J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.373 · Cited by 172
Ellebæk, E., Iversen, T. Z., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L. R., Andersen, R. S., Hadrup, S. R., Andersen, M. H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-169 · Cited by 172
Melanoma: Molecular Pathogenesis and Therapeutic Management.
Liu, Y., & Sheikh, M. S. (2014) · PubMed · Cited by 173
Targeted and Untargeted Proteomics Approaches in Biomarker Development
Sobsey, C. A., Ibrahim, S., Richard, V. R., Gaspar, V. P., Mitsa, G., Lacasse, V., Zahedi, R. P., Batist, G., & Borchers, C. H. (2019) · PROTEOMICS · doi:10.1002/pmic.201900029 · Cited by 183
Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0896 · Cited by 171
Zheng, Z., Liu, H., Zhai, S., Zhang, H., Shan, G., Kwok, R. T. K., Ma, C., Sung, H. H. Y., Williams, I. D., Lam, J. W. Y., et al. (2020) · Chemical Science · doi:10.1039/c9sc06441a · Cited by 172
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 177
Trametinib: a MEK inhibitor for management of metastatic melanoma
Rutkowski, P. L., Ługowska, I., Koseła-Paterczyk, H., & Kozak, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s72951 · Cited by 178
The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
Kim, A., & Cohen, M. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1201057 · Cited by 178
Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors
Mincu, R. I., Mahabadi, A. A., Michel, L., Mrotzek, S. M., Schadendorf, D., Rassaf, T., & Totzeck, M. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8890 · Cited by 175
Self-citationVörsmann, H., Groeber, F., Walles, H., Busch, S., Beissert, S., Walczak, H., & Kulms, D. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.249 · Cited by 168
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Watson, I. R., Li, L., Cabeceiras, P. K., Mahdavi, M., Gutschner, T., Genovese, G., Wang, G., Fang, Z., Tepper, J. M., Stemke‐Hale, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1232-t · Cited by 173
Dabrafenib and Trametinib, Alone and in Combination for BRAF -Mutant Metastatic Melanoma
Menzies, A. M., & Long, G. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2054 · Cited by 179
Mittapalli, R. K., Vaidhyanathan, S., Sane, R., & Elmquist, W. F. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192195 · Cited by 168
Fragment Based Drug Design: From Experimental to Computational Approaches
Kumar, A., Voet, A. R. D., & Zhang, K. Y. J. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803530467 · Cited by 174
Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers
Wang, Q., Jia, P., Li, F., Chen, H., Ji, H., Hucks, D., Dahlman, K. B., Pao, W. J., & Zhao, Z. (2013) · Genome Medicine · doi:10.1186/gm495 · Cited by 167
Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity
Carvajal, R. D., Spencer, S. A., & Lydiatt, W. M. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0034 · Cited by 171
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Paraiso, K. H. T., Haarberg, H. E., Wood, E. R., Rebecca, V. W., Chen, Y. A., Xiang, Y., Ribas, A., Lo, R. S., Weber, J. S., Sondak, V. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2612 · Cited by 175
Self-citationMiller, J. A., Bennett, E., Xiao, R., Kotecha, R. R., Chao, S. T., Vogelbaum, M. A., Barnett, G. H., Angelov, L., Murphy, E. S., Yu, J. S., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.08.039 · Cited by 169
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D. T., Hu, Y., Zhong, W., Randell, S., Sadek, N. L., et al. (2017) · Nature · doi:10.1038/nature24040 · Cited by 168
Self-citationTumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 178
Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth
Schöckel, L., Glasauer, A., Basit, F., Bitschar, K., Truong, H., Erdmann, G., Algire, C., Hägebarth, A., Willems, P. H., Kopitz, C., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0138-0 · Cited by 161
Galanis, E., Markovic, S. N., Suman, V. J., Nuovo, G. J., Vile, R. G., Kottke, T. J., Nevala, W. K., Thompson, M. A., Lewis, J. E., Rumilla, K. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.146 · Cited by 167
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Villanueva, J., Vultur, A., & Herlyn, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1243 · Cited by 168
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2012) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 180
Ocaña, A., Vera-Badillo, F., Al-Mubarak, M., Templeton, A. J., Corrales‐Sánchez, V., Díez-González, L., Cuenca-López, M. D., Šeruga, B., Pandiella, A., & Amir, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095219 · Cited by 169
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 179
BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma
Dahiya, S. M., Haydon, D. H., Alvarado, D. M., Gurnett, C. A., Gutmann, D. H., & Leonard, J. R. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1120-y · Cited by 167
Falchook, G. S., Trent, J. C., Heinrich, M. C., Beadling, C., Patterson, J., Bastida, C. C., Blackman, S., & Kurzrock, R. (2013) · Oncotarget · doi:10.18632/oncotarget.864 · Cited by 166
Robert, C., Dummer, R., Gutzmer, R., Lorigan, P. C., Kim, K. B., Nyakas, M., Arance, A. M., Liszkay, G., Schadendorf, D., Cantarini, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70237-7 · Cited by 170
Self-citationWargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., & Sullivan, R. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.007 · Cited by 172
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
Yates, L. R., Seoane, J., Tourneau, C. L., Siu, L. L., Marais, R., Michiels, S., Soria, J., Campbell, P. J., Normanno, N., Scarpa, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx707 · Cited by 167
The treatment of advanced melanoma: Current approaches and new challenges
Boutros, A., Croce, E., Ferrari, M., Gili, R., Massaro, G., Marconcini, R., Arecco, L., Tanda, E. T., & Spagnolo, F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104276 · Cited by 180
Pathogenesis of Langerhans Cell Histiocytosis
Badalian‐Very, G., Vergilio, J., Fleming, M. D., & Rollins, B. J. (2012) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163959 · Cited by 168
Melanoma: New Insights and New Therapies
Nikolaou, V. A., Stratigos, A., Flaherty, K. T., & Tsao, H. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.421 · Cited by 164
Self-citationIpilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 166
Ipilimumab for Patients With Advanced Mucosal Melanoma
Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N. H., Panageas, K. S., Lawrence, D. P., Ibrahim, N., Flaherty, K. T., Sullivan, R. J., Ott, P. A., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0464 · Cited by 165
Self-citationAberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Micevic, G., Theodosakis, N., & Bosenberg, M. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0332-8 · Cited by 171
Phenotype Switching in Melanoma: Implications for Progression and Therapy
Li, F. Z., Dhillon, A. S., Anderson, R. L., McArthur, G. A., & Ferrao, P. T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00031 · Cited by 164
Self-citationBucheit, A., Chen, G., Siroy, A. E., Tetzlaff, M., Broaddus, R., Milton, D., Fox, P., Bassett, R., Hwu, P., Gershenwald, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1027 · Cited by 162
Ultraviolet A and Photosensitivity during Vemurafenib Therapy
Dummer, R., Rinderknecht, J. D., & Goldinger, S. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1113752 · Cited by 164
Self-citationMelanoma metastasis: new concepts and evolving paradigms
Damsky, W., Theodosakis, N., & Bosenberg, M. (2013) · Oncogene · doi:10.1038/onc.2013.194 · Cited by 174
Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting
Talukdar, S., Bhoopathi, P., Emdad, L., Das, S. K., Sarkar, D., & Fisher, P. B. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.002 · Cited by 167
Rebecca, V. W., Sondak, V. K., & Smalley, K. S. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328351fa4d · Cited by 176
Whole Cancer Genome Sequencing by Next-Generation Methods
Ross, J. S., & Cronin, M. T. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpr1svt1vhugxw · Cited by 167
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma
Lim, S. Y., Menzies, A. M., & Rizos, H. (2017) · Cancer · doi:10.1002/cncr.30435 · Cited by 169
Carlo, V. D., Estève, J., Johnson, C. J., Girardi, F., Weir, H. K., Wilson, R. J., Minicozzi, P., Cress, R. D., Lynch, C. F., Pawlish, K. S., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa078 · Cited by 163
“A phase III randomized trial of 675 patients diagnosed with metastatic melanoma showed an overall 6-month survival of 84% (95% CI 1⁄4 78% to 89%) in those treated with vemurafenib compared with 64% (95% CI 1⁄4 56% to 73%) in those treated with dacarbazine (32).”
BackgroundUpdate on primary mucosal melanoma
Tacastacas, J. D., Bray, J., Cohen, Y. K., Arbesman, J., Kim, J. S., Koon, H. B., Honda, K. S., Cooper, K. D., & Gerstenblith, M. R. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.031 · Cited by 163
Zhang, P., Qin, X., Liu, L., Li, S., & Dong, L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.562798 · Cited by 169
Carlos, G., Anforth, R. M., Clements, A., Menzies, A. M., Carlino, M. S., Chou, S., & Fernández‐Peñas, P. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1745 · Cited by 163
The mutational landscape of phosphorylation signaling in cancer
Reimand, J., Wagih, O., & Bader, G. D. (2013) · Scientific Reports · doi:10.1038/srep02651 · Cited by 163
Genetic alterations of PTEN in human melanoma
Aguissa-Touré, A.-H., & Li, G. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0878-0 · Cited by 170
Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management
Postow, M. A., Hamid, O., & Carvajal, R. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0244-x · Cited by 161
Anker, C. J., Grossmann, K. F., Atkins, M. B., Suneja, G., Tarhini, A. A., & Kirkwood, J. M. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.01.038 · Cited by 161
Self-citationJespersen, H., Lindberg, M. F., Donia, M., Forsberg, E. M. V., Andersen, R. S., Keller, U. B., Ny, L., Svane, I. M., Nilsson, L. M., & Nilsson, J. A. (2017) · Nature Communications · doi:10.1038/s41467-017-00786-z · Cited by 161
Detection of BRAF p.V600E Mutations in Melanomas
Colomba, É., Hélias‐Rodzewicz, Z., von Deimling, A., Marin, C., Terrones, N., Pechaud, D., Surel, S., Côté, J.-F., Peschaud, F., Capper, D., et al. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.09.001 · Cited by 160
Dabrafenib and its potential for the treatment of metastatic melanoma
Murali, R., Menzies, A. M., & Long, G. V. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s38998 · Cited by 165
Leveraging big data to transform target selection and drug discovery
Chen, B., & Butte, A. J. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.318 · Cited by 165
Pediatric high-grade glioma: current molecular landscape and therapeutic approaches
Braunstein, S. E., Raleigh, D. R., Bindra, R. S., Mueller, S., & Haas-Kogan, D. A. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2393-0 · Cited by 165
Metadata
- Authors
- Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T., & McArthur, G. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institut Gustave Roussy (FR)
- The Netherlands Cancer Institute (NL)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Royal Marsden Hospital (GB)
- University of Zurich (CH)
- University of Tübingen (DE)
- European Institute of Oncology (IT)
- Tumour Institute of Tuscany (IT)
- University Health Network (CA)
- University of Manchester (GB)
- Hôpital Saint-André (FR)
- Essen University Hospital (DE)
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- Vanderbilt University (US)
- University of Pittsburgh (US)
- Plexxikon (United States) (US)
- Genentech (US)
- Massachusetts General Hospital (US)
- Peter MacCallum Cancer Centre (AU)
- ORCID
- Chapman, Paul B.
- Hauschild, Axel
- Robert, Caroline
- Haanen, John B.
- Ascierto, Paolo
- Larkin, James
- Dummer, Reinhard
- Garbe, Claus
- Testori, Alessandro
- Maio, Michele
- Hogg, David
- Lorigan, Paul
- Jouary, Thomas
- Schadendorf, Dirk
- Ribas, Antoni
- O'Day, Steven J.
- Sosman, Jeffrey A.
- Kirkwood, John M.
- Eggermont, Alexander M.M.
- Li, Jiang
- Hou, Jeannie
- Lee, Richard J.
- Flaherty, Keith T.
- McArthur, Grant A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2507-2516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549296
- OpenAlex
- W2128542677
- Cited by
- 7,720
- References
- 28
- Citations by year
- 2026: 141 · 2025: 187 · 2024: 265 · 2023: 276 · 2022: 401 · 2021: 377 · 2020: 423 · 2019: 470 · 2018: 496 · 2017: 613 · 2016: 660 · 2015: 829 · 2014: 844 · 2013: 865 · 2012: 693
- FWCI
- 332.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (K24CA097588)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, dacarbazine, metastatic melanoma, BRAF V600E mutation, BRAF inhibitors, overall survival, progression-free survival, drug toxicity, keratoacanthoma, photosensitivity
- MeSH terms
- Vemurafenib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Sulfonamides, Survival Analysis, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
